MEDIPOST, a Cambridge, MA-based biotechnology company developing therapies for inflammation-driven degenerative diseases, has raised $140M in funding in a round led by Skylake Equity Partners and Crescendo Equity Partners.
The round included participation from Korea’s growth equity fund.
Led by CEO Edward Ahn, MEDIPOST develops allogeneic, umbilical cord blood-derived mesenchymal stem cell (MSC) therapies and a pipeline of regenerative medicine built on its proprietary stem cell technology platform with a focus on therapeutic approaches for inflammation-driven and degenerative diseases. Its investigational MSC therapy is being developed to treat symptomatic cartilage defects in patients with knee osteoarthritis.
MEDIPOST intends to use the funds to accelerate its Phase III trial of the MSC therapy, expand scientific and operational capabilities, build infrastructure and scale manufacturing processes.
